Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER A SMITH

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1679675995
CMS profile
302642
Location
HORSEHEADS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$104,459.28

252 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER A SMITH

NPI 1679675995 · CMS profile ID 302642

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

HORSEHEADS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER A SMITH, NPI 1679675995, CMS profile ID 302642. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHRISTOPHER A SMITH, NPI 1679675995, CMS profile ID 302642. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHRISTOPHER A SMITH, NPI 1679675995, CMS profile ID 302642, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1679675995?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

252 matching records · $104,459.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 252 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 252.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CSL Behring $27.4108/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940895217 CMS
AstraZeneca Pharmaceuticals LP $196.0808/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920242103 CMS
AstraZeneca Pharmaceuticals LP $15.0008/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920245853 CMS
AstraZeneca Pharmaceuticals LP $113.5008/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920261691 CMS
AstraZeneca Pharmaceuticals LP $120.5308/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920263717 CMS
AstraZeneca Pharmaceuticals LP $14.9908/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920249325 CMS
GlaxoSmithKline, LLC. $1.1708/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945096355 CMS
Amgen Inc. $12.3308/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939438255 CMS
GlaxoSmithKline, LLC. $8.9808/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945096303 CMS
Horizon Therapeutics plc $23.0008/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937698827 CMS
PFIZER INC. $18.3008/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949238357 CMS
PFIZER INC. $2.3508/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949256623 CMS
ABBVIE INC. $18.8608/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891625541 CMS
Teva Pharmaceuticals USA, Inc. $9.7307/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954612446 CMS
AstraZeneca Pharmaceuticals LP $17.3507/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920255015 CMS
Regeneron Healthcare Solutions, Inc. $467.0007/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927411623 CMS
OptiNose US, Inc. $18.2907/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928142689 CMS
GENZYME CORPORATION $28.6107/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817713 CMS
Amgen Inc. $16.1807/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939438249 CMS
Regeneron Healthcare Solutions, Inc. $4,203.0007/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927411613 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.3607/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955832533 CMS
ABBVIE INC. $22.7107/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891625539 CMS
AstraZeneca Pharmaceuticals LP $14.4107/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920229393 CMS
Regeneron Healthcare Solutions, Inc. $17.8407/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927411605 CMS
Amgen Inc. $24.9907/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939438241 CMS
AstraZeneca Pharmaceuticals LP $3,700.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920255589 CMS
GlaxoSmithKline, LLC. $14.7306/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945096295 CMS
AstraZeneca Pharmaceuticals LP $146.2506/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920227523 CMS
AstraZeneca Pharmaceuticals LP $113.3406/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920234409 CMS
AstraZeneca Pharmaceuticals LP $226.4406/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920248831 CMS
Bio Products Laboratory USA, Inc. $14.2206/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937420085 CMS
OptiNose US, Inc. $19.6006/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928142675 CMS
GENZYME CORPORATION $45.1506/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817715 CMS
GENZYME CORPORATION $4,203.0006/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817717 CMS
GENZYME CORPORATION $143.3606/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817719 CMS
PFIZER INC. $20.8606/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949178259 CMS
PFIZER INC. $24.0106/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949618761 CMS
GlaxoSmithKline, LLC. $10.5606/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945096323 CMS
AstraZeneca Pharmaceuticals LP $12.2506/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920233819 CMS
GENZYME CORPORATION $104.3206/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817721 CMS
GENZYME CORPORATION $3,269.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817723 CMS
GENZYME CORPORATION $4.5006/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938817725 CMS
Teva Pharmaceuticals USA, Inc. $10.7106/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954612581 CMS
GlaxoSmithKline, LLC. $19.9706/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945096325 CMS
Grifols USA, LLC $23.6006/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918681275 CMS
Grifols USA, LLC $17.2206/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918691007 CMS
Genentech, Inc. $190.5406/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662925 CMS
Genentech, Inc. $280.0006/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662831 CMS
Genentech, Inc. $1,275.1606/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662895 CMS
Genentech, Inc. $190.5406/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $86,953.82 232
PY2020 $35,106.51 166
PY2021 $51,224.18 157
PY2022 $104,459.28 252
PY2023 $107,599.06 266
PY2024 $124,871.77 261
PY2025 $112,211.01 265

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,650,793.03 108
PY2024 Principal investigator $3,249,344.65 151
PY2023 Principal investigator $5,560,565.13 232
PY2022 Principal investigator $4,620,075.95 221
PY2021 Principal investigator $764,750.18 79
PY2020 Principal investigator $248,688.67 85
PY2019 Principal investigator $235,242.43 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

108 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $79.62 12/31/2025 Non-covered Recipient Entity
Certified Research Associates
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1232933230
Principal investigator 1 Merck Sharp & Dohme LLC $79.62 12/31/2025 Non-covered Recipient Entity
Corning Center For Clinical Research
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1232933402
Principal investigator 1 Merck Sharp & Dohme LLC $0.38 12/31/2025 Non-covered Recipient Entity
Certified Research Associates
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine wi No dispute reported 06/30/2026 1232934292
Principal investigator 1 Merck Sharp & Dohme LLC $0.32 12/31/2025 Non-covered Recipient Entity
Corning Center for Clinical Research
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine wi No dispute reported 06/30/2026 1232934516
Principal investigator 1 Merck Sharp & Dohme LLC $47,408.00 12/31/2025 Non-covered Recipient Entity
Certified Research Associates
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232937520
Principal investigator 1 PFIZER INC. $4,758.75 12/31/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228723568
Principal investigator 1 PFIZER INC. $47,801.59 12/31/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228735745
Principal investigator 1 PFIZER INC. $3,807.00 12/31/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228745158
Principal investigator 1 PFIZER INC. $35,874.31 12/31/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228746141
Principal investigator 1 PFIZER INC. $27,600.75 12/24/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228749993
Principal investigator 1 PFIZER INC. $64,719.00 12/17/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228722766
Principal investigator 1 PFIZER INC. $59,008.50 12/17/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228730942
Principal investigator 1 PFIZER INC. $143,407.25 12/16/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228733799
Principal investigator 1 PFIZER INC. $86,953.50 12/16/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228746268
Principal investigator 1 Merck Sharp & Dohme LLC $37,289.60 12/15/2025 Non-covered Recipient Entity
Certified Research Associates
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232937518
Principal investigator 1 PFIZER INC. $2,775.00 12/12/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228746870
Principal investigator 1 PFIZER INC. $53,298.00 11/27/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228738365
Principal investigator 1 PFIZER INC. $13,324.50 11/27/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228739177
Principal investigator 1 PFIZER INC. $5,233.25 11/26/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714489
Principal investigator 1 PFIZER INC. $200.00 11/26/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228728345
Principal investigator 1 PFIZER INC. $234.00 11/17/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228723632
Principal investigator 1 PFIZER INC. $292.50 11/17/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228724784
Principal investigator 1 PFIZER INC. $303.00 11/17/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228728641
Principal investigator 1 PFIZER INC. $234.00 11/14/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228723036
Principal investigator 1 PFIZER INC. $303.00 11/14/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228723740
Principal investigator 1 PFIZER INC. $292.50 11/14/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228728339
Principal investigator 1 PFIZER INC. $11.70 11/11/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228723630
Principal investigator 1 PFIZER INC. $11.70 11/11/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228724780
Principal investigator 1 PFIZER INC. $378.75 11/11/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228724782
Principal investigator 1 PFIZER INC. $378.75 11/11/2025 Non-covered Recipient Entity
Finger Lakes Medical Research
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228724858
Principal investigator 1 GlaxoSmithKline, LLC. $1,836.85 11/07/2025 Non-covered Recipient Entity
FINGER LAKES MEDICAL RESEARCH
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192130441
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 11/07/2025 Non-covered Recipient Entity
FINGER LAKES MEDICAL RESEARCH
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192130449
Principal investigator 1 GlaxoSmithKline, LLC. $6,500.00 11/07/2025 Non-covered Recipient Entity
FINGER LAKES MEDICAL RESEARCH
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192133510
Principal investigator 1 GlaxoSmithKline, LLC. $375.00 11/07/2025 Non-covered Recipient Entity
FINGER LAKES MEDICAL RESEARCH
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192133518
Principal investigator 1 PFIZER INC. $500.00 11/05/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228729504
Principal investigator 1 PFIZER INC. $2,360.00 11/01/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228729812
Principal investigator 1 PFIZER INC. $2,594.55 11/01/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228739331
Principal investigator 1 PFIZER INC. $10,469.80 10/31/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228741778
Principal investigator 1 PFIZER INC. $19,895.20 10/25/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228740923
Principal investigator 1 PFIZER INC. $7,535.88 10/25/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228741643
Principal investigator 1 PFIZER INC. $3,385.80 10/09/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228741537
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 10/08/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192130435
Principal investigator 1 GlaxoSmithKline, LLC. $2,901.00 10/08/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192130453
Principal investigator 1 SANOFI PASTEUR INC. $10,000.00 10/03/2025 Non-covered Recipient Entity
Finger Lakes Medical Research, Pllc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers No dispute reported 06/30/2026 1226101011
Principal investigator 1 SANOFI PASTEUR INC. $50.00 10/03/2025 Non-covered Recipient Entity
Finger Lakes Medical Research, Pllc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers No dispute reported 06/30/2026 1226101018
Principal investigator 1 SANOFI PASTEUR INC. $500.00 10/03/2025 Non-covered Recipient Entity
Finger Lakes Medical Research, Pllc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers No dispute reported 06/30/2026 1226101024
Principal investigator 1 SANOFI PASTEUR INC. $410.00 10/03/2025 Non-covered Recipient Entity
Finger Lakes Medical Research, Pllc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers No dispute reported 06/30/2026 1226101030
Principal investigator 1 PFIZER INC. $1,228.00 09/24/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228762044
Principal investigator 1 PFIZER INC. $1,500.00 08/21/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228766259
Principal investigator 1 PFIZER INC. $222.75 08/20/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228767694
Principal investigator 1 PFIZER INC. $1,376.27 08/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228723888
Principal investigator 1 PFIZER INC. $1,169.27 08/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228724130
Principal investigator 1 PFIZER INC. $10,242.45 08/06/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228784985
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 08/06/2025 Non-covered Recipient Entity
SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044766
Principal investigator 1 PFIZER INC. $131.75 08/04/2025 Non-covered Recipient Entity
Smith Allergy Asthma Spec
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228714305
Principal investigator 1 PFIZER INC. $199.32 08/04/2025 Non-covered Recipient Entity
Smith Allergy Asthma Spec
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228714375
Principal investigator 1 PFIZER INC. $757.50 08/04/2025 Non-covered Recipient Entity
Smith Allergy Asthma Spec
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228714491
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 07/30/2025 Non-covered Recipient Entity
SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044802
Principal investigator 1 PFIZER INC. $5,676.12 07/25/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228782383
Principal investigator 1 PFIZER INC. $438.75 07/23/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228773661
Principal investigator 1 PFIZER INC. $3,412.80 07/16/2025 Non-covered Recipient Entity
Smith Allergy Asthma Specialists
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228714377
Principal investigator 1 PFIZER INC. $300.00 07/16/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228765153
Principal investigator 1 PFIZER INC. $1,201.50 07/16/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228783872
Principal investigator 1 PFIZER INC. $38,967.88 07/11/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228762973
Principal investigator 1 PFIZER INC. $33,277.30 07/11/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228784089
Principal investigator 1 PFIZER INC. $129.87 07/08/2025 Non-covered Recipient Entity
Corning Ctr for Clin Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714301
Principal investigator 1 PFIZER INC. $110.79 07/08/2025 Non-covered Recipient Entity
Corning Ctr for Clin Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714303
Principal investigator 1 PFIZER INC. $832.98 06/27/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228785561
Principal investigator 1 PFIZER INC. $199,225.09 06/21/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228776145
Principal investigator 1 PFIZER INC. $159,982.60 06/21/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228790847
Principal investigator 1 PFIZER INC. $2,910.64 06/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228777144
Principal investigator 1 PFIZER INC. $8,233.16 06/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228791629
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 06/13/2025 Non-covered Recipient Entity
SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044764
Principal investigator 1 PFIZER INC. $172,341.00 06/06/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228775253
Principal investigator 1 PFIZER INC. $278,830.34 06/06/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228790642
Principal investigator 1 PFIZER INC. $10,232.90 05/28/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228771960
Principal investigator 1 PFIZER INC. $8,326.50 05/28/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228772458
Principal investigator 1 AstraZeneca Pharmaceuticals LP $93,111.47 05/13/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185547275
Principal investigator 1 PFIZER INC. $2,191.88 05/07/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228781578
Principal investigator 1 PFIZER INC. $555.32 05/06/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228763474
Principal investigator 1 PFIZER INC. $555.32 05/06/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228783375
Principal investigator 1 PFIZER INC. $1,643.91 05/02/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228764707
Principal investigator 1 PFIZER INC. $3,311.83 05/01/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228764997
Principal investigator 1 PFIZER INC. $4,089.26 05/01/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228778179
Principal investigator 1 PFIZER INC. $309,081.39 04/30/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228795335
Principal investigator 1 PFIZER INC. $230,475.69 04/29/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228720301
Principal investigator 1 PFIZER INC. $661.50 04/26/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228798197
Principal investigator 1 PFIZER INC. $72,990.85 04/10/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228778720
Principal investigator 1 PFIZER INC. $72,640.05 04/10/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228781387
Principal investigator 1 PFIZER INC. $1,731.64 04/08/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228723026
Principal investigator 1 PFIZER INC. $626.90 04/08/2025 Non-covered Recipient Entity
Corning Center for Clinical
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228770968
Principal investigator 1 PFIZER INC. $3,261.26 04/08/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228779473
Principal investigator 1 PFIZER INC. $4,866.10 04/01/2025 Non-covered Recipient Entity
Christopher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228779811
Principal investigator 1 PFIZER INC. $9,572.20 04/01/2025 Non-covered Recipient Entity
Christpher A Smith MD
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228794588
Principal investigator 1 PFIZER INC. $10,893.91 03/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228766369
Principal investigator 1 PFIZER INC. $20,188.78 03/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228796329
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
SMITH ALLERGY AND ASTHMA OF CENTRAL NEW YORK PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044800
Principal investigator 1 PFIZER INC. $16,052.30 02/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228752664
Principal investigator 1 PFIZER INC. $23,661.44 02/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228757974
Principal investigator 1 PFIZER INC. $101.25 02/19/2025 Non-covered Recipient Entity
Smith Allergy Athsma of Central New York PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228749731
Principal investigator 1 AstraZeneca UK Limited $52,575.90 02/13/2025 Non-covered Recipient Entity
FINGER LAKES MEDICAL RESEARCH PLLC
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185547273
Principal investigator 1 PFIZER INC. $1,500.00 02/12/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228770278
Principal investigator 1 PFIZER INC. $1,948.51 02/05/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228750190
Principal investigator 1 PFIZER INC. $16,923.28 01/30/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228798267
Principal investigator 1 PFIZER INC. $34,780.49 01/30/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228800799
Principal investigator 1 PFIZER INC. $300.00 01/29/2025 Non-covered Recipient Entity
Smith Allergy Asthma of Central New YorkPLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228801538
Principal investigator 1 PFIZER INC. $661.50 01/15/2025 Non-covered Recipient Entity
Smith Allergy Athsma of Central New York PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228801937
Principal investigator 1 PFIZER INC. $5,367.65 01/09/2025 Non-covered Recipient Entity
Smith Allergy Athsma of Central New York PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228799643